Delombaerde, D.; De Sutter, J.; Croes, L.; Vervloet, D.; Moerman, V.; Van de Veire, N.; Willems, A.-M.; Wouters, K.; Peeters, M.; Prenen, H.;
et al. Extensive CArdioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study. Pharmaceuticals 2023, 16, 625.
https://doi.org/10.3390/ph16040625
AMA Style
Delombaerde D, De Sutter J, Croes L, Vervloet D, Moerman V, Van de Veire N, Willems A-M, Wouters K, Peeters M, Prenen H,
et al. Extensive CArdioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study. Pharmaceuticals. 2023; 16(4):625.
https://doi.org/10.3390/ph16040625
Chicago/Turabian Style
Delombaerde, Danielle, Johan De Sutter, Lieselot Croes, Delphine Vervloet, Veronique Moerman, Nico Van de Veire, Anne-Marie Willems, Kristien Wouters, Marc Peeters, Hans Prenen,
and et al. 2023. "Extensive CArdioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study" Pharmaceuticals 16, no. 4: 625.
https://doi.org/10.3390/ph16040625
APA Style
Delombaerde, D., De Sutter, J., Croes, L., Vervloet, D., Moerman, V., Van de Veire, N., Willems, A.-M., Wouters, K., Peeters, M., Prenen, H., & Vulsteke, C.
(2023). Extensive CArdioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study. Pharmaceuticals, 16(4), 625.
https://doi.org/10.3390/ph16040625